Hosted on MSN14d
MESO Stock Surges 80% in a Month After FDA Approval of GVHD DrugShares of Mesoblast Limited MESO have soared 80% in one month following the FDA approval of remestemcel-L as the only ...
Mesoblast announces that the FDA approved Ryoncil. Ryoncil is the only approved therapy for steroid-refractory acute graft versus host disease. Mesoblast Limited MESO stock is trading higher ...
Maxim raised the firm’s price target on Mesoblast (MESO) to $30 from $18 and keeps a Buy rating on the shares after the FDA approved Ryoncil as ...
Mesoblast Limited MESO announced that the FDA has approved Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in children aged two months ...
(RTTNews) - The U.S. Food and Drug Administration approved Mesoblast Limited's (MESO, MSB.AX) Ryoncil or remestemcel-L-rknd, an allogeneic (donor) bone marrow-derived mesenchymal stromal cell ...
Shares of Mesoblast Limited MESO have soared 80% in one month following the FDA approval of remestemcel-L as the only approved therapy for steroid-refractory acute graft versus host disease (SR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback